AstraZeneca said its CCP virus vaccine is safe and effective following an interim analysis of data from a U.S.-based phase three trial involving over 32,000 participants. “The vaccine was well tolerated, and the independent data safety monitoring board (DSMB) identified no safety concerns related to the vaccine,” the company said in a March 22 statement. Last week, more than a dozen nations suspended use of the AstraZeneca vaccine, called AZD1222, after a few dozen people who received the vaccine developed blood clots. The European Union’s drug regulatory agency subsequently carried out a review and concluded that, while it couldn’t rule out a direct link to thrombotic events—or blood clotting—the benefits of using the vaccine outweigh the possible risks. Following the announcement by the European Medicines Agency, countries including France, Germany, and Italy resumed their use of the shot on Friday, with senior politicians rolling up their sleeves in a bid to …